Almac to further expand Ireland campus with £30m investment

The investment will increase the good manufacturing practice (GMP) footprint at the campus by more than thrice.

Slated to be operationally ready by the start of next year, the expanded campus will see the addition of a new QC laboratory and packaging facility for commercial drug products.

It will also feature a 79,000ft² European Union (EU) distribution centre for clinical trial supply.

Almac said that the new investment complements the clinical supply and drug product development operations that are currently being provided by its global headquarters site in Craigavon, Northern Ireland.

The company also said that its European campus increases its global presence by a great extent and offers an expanded footprint within the EU for clinical trial supplies and commercial drug product operations alike.

Its new investment follows the completion of Health Products Regulatory Authority (HPRA) inspections of Almac Clinical Services Ireland and Almac Pharma Services Ireland at the new campus.

Almac Group CEO and chairman Alan Armstrong said: “Achieving these successful HPRA inspections is a key milestone. In addition, the announcement today of further expansion will ensure our current and future clients receive a seamless solution with access to the EU marketplace. 

“Crucially, this will ensure an uninterrupted service provision through any uncertainty Brexit may bring, and for the future, keeping Almac as a global leader in the life sciences sector.”

In January last year, Almac had secured the Dundalk premises as part of a global expansion strategy, aimed at meeting client demand and also for tackling any potential challenges that could arise from Brexit.

Image: Almac to invest an additional £30m to expand its European campus in Dundalk. Photo: courtesy of Almac Group.